A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

NCT00382239 · Completed

Last updated 2026-05-28

This clinical trial tests the effects of the medication LY2148568 on blood sugar control and safety in Japanese adults with type 2 diabetes over a 12-week period.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 153 people

Who can join Ages 20–75 · all sexes

Timeline Started 2006-09 · est. completion 2007-05

Where 14 sites · Japan

What this study is testing ClinicalTrials.gov NCT00382239 ↗

Description as written by the study sponsor.

This study will examine the response of several doses of LY2148568 (exenatide) and assess the effect on glucose control and safety and tolerability in Japanese patients with type 2 diabetes.

Treatments tested

exenatide (LY2148568) also known as Byetta Drug

subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
exenatide (LY2148568) also known as Byetta Drug

subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
exenatide (LY2148568) also known as Byetta Drug

subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
Placebo Drug

subcutaneous injection twice daily, 0.02 mL to 0.04 mL

Main thing measured	Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00382239 ↗